Patient Case Studies

Consult these peer-guided patient case videos to help identify adult patients for whom XIFAXAN may be an appropriate therapy.

Recognizing the Symptoms of IBS-D

Featuring Kimberly Kearns, MS, APRN, ANP-BC

IBS-D Case Study Video, Greg

Recognizing the Symptoms of IBS-D

Featuring Kimberly Kearns, MS, APRN, ANP-BC

Follow along on the journey of Greg, a 29-year-old male who was referred to a gastroenterology specialist for frequent diarrhea accompanied by abdominal pain.

Watch Video Download Case Study

The Cycle of IBS-D Symptoms

Featuring Amy L. Stewart, CRNP 

IBS-D Case Study Video, Maria

The Cycle of IBS-D Symptoms

Featuring Amy L. Stewart, CRNP 

Follow along on the journey of Maria, a 38-year-old female who presented to her primary care provider with frequent abdominal pain associated with diarrhea during the past 4 months.

Watch Video Download Case Study

Healthcare Professionals Sharing Clinical Insights

Join host Christina J. Hanson, FNP, in her conversations with fellow clinicians about clinical insights in the management of adult patients with irritable bowel syndrome with diarrhea (IBS-D).

Potential Causes of Your Adult Patients’ IBS-D Symptoms Featuring Amy Kassebaum, PA-C, MMS, RD, Northwestern Memorial Hospital

View transcript >

Potential Causes of Your Adult Patients’ IBS-D Symptoms Featuring Amy Kassebaum, PA-C, MMS, RD, Northwestern Memorial Hospital

Learn about potential factors that are thought to contribute to IBS-D symptoms.

Download podcast audio

Don’t have time to watch the full episode above? View clips below.

Bacterial Imbalance and IBS-D Symptoms

Bacterial Imbalance and IBS-D Symptoms

How XIFAXAN® (rifaximin) Is Thought to Work

How XIFAXAN® (rifaximin) Is Thought to Work

Managing Your Adult Patients’ IBS-D Symptoms Featuring Kim Orleck, PA-C, Atlanta Gastroenterology Associates

View transcript >

Managing Your Adult Patients’ IBS-D Symptoms Featuring Kim Orleck, PA-C, Atlanta Gastroenterology Associates

Recognize the recurring symptoms of IBS-D, and learn about a treatment option that may help provide relief for your appropriate patients.1,2

Download podcast audio

Don’t have time to watch the full episode above? View clips below.

Connecting With IBS-D Patients and Defining Success

Connecting With IBS-D Patients and Defining Success

Managing IBS-D With XIFAXAN® (rifaximin)

Managing IBS-D With XIFAXAN® (rifaximin)

Connecting With Your Patients Through Telehealth Featuring Kim Orleck, PA-C, Atlanta Gastroenterology Associates

View transcript >

Connecting With Your Patients Through Telehealth Featuring Kim Orleck, PA-C, Atlanta Gastroenterology Associates

Hear how these healthcare providers applied their diagnostic skills virtually and strengthened their relationships with their IBS-D patients.

Download podcast audio

Don’t have time to watch the full episode above? View the clip below.

Managing IBS-D Patients Through Telehealth

Managing IBS-D Patients Through Telehealth

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
    • HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

References: 1. XIFAXAN (rifaximin) tablets [package insert]. Bridgewater, NJ: Salix Pharmaceuticals. 2. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407.

SEE MORE

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
X
X
X
X
X
X
X
X